This tumour microenvironment-responsive drug release behaviour of the nanoparticles can potentially reduce off-target toxic effects, thus improving the safety of the Cur-Tf-PDAAm NPs as a promising drug delivery system. The gene discussed is TF; the disease is neoplasm.